GoPath Laboratories, IntegraGen’s licensing partner in the U.S., has announced that it will launch a propriety new test, miR-31now™ during the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2018 in Chicago. The miR-31now test is the first positive theranostic test for patients with metastatic colorectal cancer (mCRC). The test predicts the potential clinical benefits associated with first-line anti-EGFR therapy compared to anti-VEGF therapy or when second or further lines of treatment with anti-EGFR therapy is beneficial versus chemotherapy alone for patients with RAS wild type (WT) mCRC.
The miR-31now test quantifies the expression of the miR-31-3p in formalin-fixed, paraffin-embedded (FFPE) tumor samples using standard quantitative reverse transcription PCR (RT-qPCR). GoPath will offer miR-31now as a Laboratory Developed Test (LDT) to customers in the U.S. and Canada in conjunction with their full menu of additional tests for patients with mCRC, including KRAS and RAS mutation testing.
GoPath Labs previously signed a non-exclusive licensing agreement with IntegraGen enabling them to offer a test based on IntegraGen’s intellectual property associated with the miR-31-3p biomarker. IntegraGen will continue to sell and distribute the company’s IVD CE Marked miRpredX 31-3p kit in the EU and other regions.
Click here to view press release.